Business Context and Reporting Period
This Form 8-K Current Report was filed by MacroGenics, Inc. on November 13, 2017. The filing addresses a specific corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on management changes and does not contain financial performance data.
Material Changes
- Board Composition: The Board of Directors increased its size from eight to nine members.
- New Appointment: Jay Siegel, M.D., was appointed as a Class I director, effective immediately. His term extends until the 2020 Annual Meeting of Stockholders.
- Compensation Structure: Dr. Siegel received an annual retainer of $35,000 (prorated from the appointment date) and an option to purchase 20,000 shares of common stock.
- Stock Option Details: The option exercise price is $17.85 per share (the closing market price on the grant date). Vesting occurs in 12 equal monthly portions starting one year after the grant date, contingent on continued service.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No risks, contingencies, or unusual items were disclosed in this specific report. The document confirms there are no undisclosed arrangements regarding Dr. Siegel's selection.
Investor Verification Checklist
- Verify the impact of the increased Board size on corporate governance dynamics.
- Review the vesting schedule and exercise price ($17.85) of the 20,000 share option granted to Dr. Siegel.
- Confirm the absence of any undisclosed related-party transactions involving the new director.
- Note that this filing does not update financial results; refer to the most recent 10-Q or 10-K for financial metrics.